IL6 and breast cancer: Further, the role of STAT-3 pathway in IL-6 mediated CSC enrichment in breast cancer was confirmed by using Stattic, a STAT-3 inhibitor, and it was observed that pre-treatment with Stattic attenuated activated macrophage derived IL-6 mediated CSC enrichment in breast cancer.